» Articles » PMID: 36276636

Near-infrared Photoimmunotherapy: Design and Potential Applications for Cancer Treatment and Beyond

Overview
Journal Theranostics
Date 2022 Oct 24
PMID 36276636
Authors
Affiliations
Soon will be listed here.
Abstract

Near-infrared photoimmunotherapy (NIR-PIT) is a newly developed cancer treatment modality based on a target-specific photosensitizer conjugate (TSPC) composed of an NIR phthalocyanine photosensitizer and an antigen-specific recognition system. NIR-PIT has predominantly been used for targeted therapy of tumors via local irradiation with NIR light, following binding of TSPC to antigen-expressing cells. Physical stress-induced membrane damage is thought to be a major mechanism underlying NIR-PIT-triggered photokilling. Notably, NIR-PIT can rapidly induce immunogenic cell death and activate the adaptive immune response, thereby enabling its combination with immune checkpoint inhibitors. Furthermore, NIR-PIT-triggered "super-enhanced permeability and retention" effects can enhance drug delivery into tumors. Supported by its potential efficacy and safety, NIR-PIT is a rapidly developing therapeutic option for various cancers. Hence, this review seeks to provide an update on the (i) broad range of target molecules suitable for NIR-PIT, (ii) various types of receptor-selective ligands for designing the TSPC "magic bullet," (iii) NIR light parameters, and (iv) strategies for enhancing the efficacy of NIR-PIT. Moreover, we review the potential application of NIR-PIT, including the specific design and efficacy in 19 different cancer types, and its clinical studies. Finally, we summarize possible NIR-PIT applications in noncancerous conditions, including infection, pain, itching, metabolic disease, autoimmune disease, and tissue engineering.

Citing Articles

Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research.

Allen D, Szoo M, van Bergen T, Seppelin A, Oh J, Saad M Antib Ther. 2025; 8(1):68-85.

PMID: 39958565 PMC: 11826922. DOI: 10.1093/abt/tbaf001.


Enhancing the efficacy of near-infrared photoimmunotherapy through intratumoural delivery of CD44-targeting antibody-photoabsorber conjugates.

Adachi Y, Miyake K, Ohira K, Satoh S, Masuhiro K, Edahiro R EBioMedicine. 2025; 112:105566.

PMID: 39848206 PMC: 11795636. DOI: 10.1016/j.ebiom.2025.105566.


Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions.

Ding J, Yeong C Front Oncol. 2024; 14:1504139.

PMID: 39703856 PMC: 11655346. DOI: 10.3389/fonc.2024.1504139.


Ginsenoside Rg3 combined with near-infrared photothermal reversal of multidrug resistance in breast cancer MCF-7/ADR cells.

Chang Y, Fu Q, Lu Z, Jin Q, Jin T, Zhang M Food Sci Nutr. 2024; 12(8):5750-5761.

PMID: 39139957 PMC: 11317707. DOI: 10.1002/fsn3.4205.


Light-Assisted "Nano-Neutrophils" with High Drug Loading for Targeted Cancer Therapy.

Fan D, Wang S, Huang R, Liu X, He H, Zhang G Int J Nanomedicine. 2023; 18:6487-6502.

PMID: 37965278 PMC: 10642559. DOI: 10.2147/IJN.S432854.


References
1.
Bauerschlag D, Meinhold-Heerlein I, Maass N, Bleilevens A, Brautigam K, Al Rawashdeh W . Detection and Specific Elimination of EGFR Ovarian Cancer Cells Using a Near Infrared Photoimmunotheranostic Approach. Pharm Res. 2017; 34(4):696-703. DOI: 10.1007/s11095-017-2096-4. View

2.
Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

3.
Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis E, Terracciano L . Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. 2008; 129(6):899-906. DOI: 10.1309/HCQWPWD50XHD2DW6. View

4.
Nakajima T, Sano K, Choyke P, Kobayashi H . Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Theranostics. 2013; 3(6):357-65. PMC: 3677407. DOI: 10.7150/thno.5908. View

5.
Sato K, Watanabe R, Hanaoka H, Nakajima T, Choyke P, Kobayashi H . Comparative effectiveness of light emitting diodes (LEDs) and Lasers in near infrared photoimmunotherapy. Oncotarget. 2016; 7(12):14324-35. PMC: 4924718. DOI: 10.18632/oncotarget.7365. View